Business
LSL PHARMA GROUP ANNOUNCES ACQUISITION OF JUNO OTC INC. AND A BROKERED PRIVATE PLACEMENT OF CONVERTIBLE DEBENTURES OF $11M
LSL PHARMA GROUP ANNOUNCES ACQUISITION OF JUNO OTC INC. AND A BROKERED PRIVATE PLACEMENT OF CONVE...
About this update from Lsl Pharma Group Inc
[{"type":"text","content":"\n\n\nLSL PHARMA GROUP ANNOUNCES ACQUISITION OF JUNO OTC INC. AND A BROKERED PRIVATE PLACEMENT OF CONVERTIBLE DEBENTURES OF $11M\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\nCanada NewsWire\n\n\n\n/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSMEMINATION IN THE UNITED STATES/\nBOUCHERVILLE, QC, Dec. 17, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (The \"Corporation\" or \"LSL Pharma\"), a Canadian integrated pharmaceutical company, is pleased to announce that it has entered into an arm's length letter of intent dated December 16, 2025 (the \"Agreement\") with Juno Pharmaceuticals LP (the \"Seller\"), to acquire (the \"Acquisition\") all of the outstanding shares of Juno OTC Inc. (\"Juno OTC\"), a Toronto based wholly owned subsidiary of the Seller, for a total purchase price of $5 million (the \"Purchase Price\") to be paid to the Seller. As set forth in the Agreement, the Purchase Price will be paid as follows: (i) $2,500,000 in cash on the closing date of the Acquisition (the \"Acquisition Closing Date\"); (ii) such number of Class \"A\" common shares of the Corporation (the \"Common Shares\") on the Acquisition Closing Date as is equal to $2,000,000 divided by the volume-weighted average price of the Common Shares for the twenty (20) consecutive trading days preceding the execution of the definitive share purchase agreement; and (iii) $500,000 in cash on January 1, 2027 (the \"Purchase Price Balance\"). The Purchase Price Balance of $500,000 payable on January 1, 2027 will be adjusted to reflect variations in working capital, if any.\nOverview of the Acquisition\nThrough this acquisition, LSL Pharma becomes a key supplier to most Canadian pharmacy banners and its revenues will immediately benefit from the existing Juno OTC business. Juno OTC adds a pipeline of innovative products to LSL Pharma, including over 40 Health Canada approved OTC drugs, natural health products and medical devices to the LSL Pharma business. The integration of Juno OTC will enable the Corporation to expand its customer base by adding a...